Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning, everyone. Damian here with an in-depth preview of a certain annual biotech conference, a look at the cutting edge of obesity drug development, and year’s first IPO filing.
The need-to-know this morning
- Eli Lilly issued an “open letter” warning against the use of its GLP-1 drugs Mounjaro and Zepbound for “cosmetic weight loss.”
- A judge recommended the dismissal of a defamation lawsuit filed by Cassava Sciences against two neuroscientists, Geoffrey Pitt and David Bredt, who had petitioned the FDA to halt the development of the company’s experimental Alzheimer’s drug.
- It’s a big morning for “2024 corporate update” press releases from biotech companies — too many to list here.
Your guide to #JPM24
Will there be deals? Why is Nvidia here? And can biotech’s good vibes survive?
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect